HCP Connect Contributor
Dr. Meera Pillai
Dr. Meera Pillai contributes oncology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.
Recent Drug Updates
20 total
Oncology
Osimertinib and Pembrolizumab: New First-Line Strategies for NSCLC in 2026
Osimertinib and pembrolizumab are pivotal in NSCLC first-line treatment, improving outcomes based on biomarker selection.
Oncology
NCCN Updates Guidelines: ESR1 Mutation Testing for Breast Cancer Management
NCCN updates guidelines for ESR1 mutation testing in breast cancer: new targeted therapies vepdegestrant and elacestrant.
Oncology
FDA Panel Recommends Capivasertib for PTEN-Deficient mHSPC: New Combination Therapy with Abiraterone
FDA panel recommends capivasertib for PTEN-deficient mHSPC: a new combination therapy with abiraterone.
Oncology
Liquid Biopsy for ESR1 Mutation Testing: Key Insights for Breast Cancer Management
Liquid biopsy for ESR1 mutation testing is crucial for managing ER+ breast cancer, guiding treatment decisions for patients.
Oncology
FDA Approves LYNOZYFIC for Multiple Myeloma: 80% Response Rate in Relapsed Patients
FDA approves LYNOZYFIC for multiple myeloma: 80% response rate in relapsed patients, enhancing treatment options.
Medical Research
Remote Monitoring Cuts Cancer Surgery Recovery Time
Discover how remote perioperative monitoring improves outcomes for cancer surgery patients, reducing recovery time and enhancing care.
Oncology
Targeting TMOD2 to Halt Colorectal Cancer Spread
Discover the crucial role of TMOD2 in colorectal cancer progression and metastasis, and how understanding its mechanisms can inform targeted treatment strategies for improved patie...
Oncology
Lipid Levels Linked to 30% Lower Lymphoma Risk
Discover how abnormal lipid levels impact lymphoid malignancy risk in a study of 403,625 UK Biobank participants with 10.5 years of follow-up.
Oncology
ctDNA Guides Surgery for Recurrence
Learn how circulating tumor DNA can predict metastases and inform surgical decisions for better patient outcomes in oncology.
Oncology
Detect MSI in CRC with 1-Hour Molecular Test
Quickly identify microsatellite instability-high colorectal cancer with a rapid molecular test, guiding targeted therapy decisions for patients.
Oncology
Improve Patient Outcomes with Early Palliative Care
Learn how early palliative care integration can enhance patient quality of life and reduce unnecessary hospitalizations in oncology practices
Oncology
Similar Survival in ES-SCLC with Cis/Carbo Plus Etoposide
Real-world analysis shows comparable efficacy between cisplatin and carboplatin with etoposide in extensive-stage small cell lung cancer treatment.
Oncology
82% Complete Response in BCG-Unresponsive NMIBC
Discover a new treatment option for high-risk BCG-unresponsive NMIBC, offering a complete response in 82% of patients and potentially reducing cystectomy rates.
Medical Research
T Cell Exclusion Mechanisms in B Cell Lymphomas
Discover how ATR-dependent determinants exclude T cells from germinal center dark zones in aggressive B cell lymphomas, shedding light on lymphoma biology and potential therapeutic...
Medical Research
New Therapies May Reactivate Immune System in Resistant Melanoma
Researchers identify potential new strategies to overcome immunotherapy resistance in advanced melanoma, offering hope for improved patient outcomes.
Wellness
Inpatient Treatment Yields Better Outcomes for Dual Diagnosis
Learn how inpatient treatment can improve recovery outcomes for patients with dual diagnosis, prioritizing well-being and reducing recidivism rates effectively.
Healthcare Business
ACA Coverage Cuts Young Adult ED Visits by 30%
Discover how the Affordable Care Act's dependent coverage extension impacts substance-associated ED visits among young adults, reducing healthcare utilization and costs.
Healthcare Business
Cut NSCLC Resistance Rates by 30% with Dual Therapy
Learn how combining two therapies can reduce EGFR and MET resistance in NSCLC, improving treatment strategies and patient outcomes in second-line settings.
Oncology
48% Response Rate in ES-SCLC with Novel Therapy
Ifinatamab deruxtecan yields remarkable efficacy in extensive-stage small cell lung cancer, with a 48.2% overall response rate in previously treated patients.
Digital Health
AI Boosts Cardiac Cath Outcomes by 30%
Discover how AI-powered cardiac catheterization labs improve patient care and outcomes, enhancing interventional cardiology with advanced research and expertise.